title: Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
abstract: OBJECTIVE
  BACH2, a B-cell-specific transcription repressor, is abundantly expressed in lymphocytes of B-cell lineage as well as B-cell lymphoma cell lines. BACH2 possesses an inhibitory effect on proliferation of Raji cell lines derived from Burkitt's lymphoma. In this study, the prognostic significance of BACH2 expression was examined in diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  BACH2 expression was immunohistochemically examined on the paraffin-embedded sections obtained by biopsy from 108 patients (62 males and 46 females; age range, 23 to 85 years) with DLBCL. Staining intensity in the cytoplasm of the tumor cells was categorized as equal to or stronger (level 1) or weaker (level 2) than that in the endothelial cells in the same specimens.
  
  
  RESULTS
  Level 1 and 2 expression of BACH2 was found in 32.4% and 67.6% of patients, respectively. Patients with level 1 expression showed significantly better disease-free and overall survival rate than those with level 2 expression (both P < .05). Multivariate analysis revealed BACH2 expression level together with performance status, elevated serum level of lactate dehydrogenase, and treatment response to be independent factors for prognosis of the patients.
  
  
  CONCLUSIONS
  BACH2 expression level is a useful marker to predict disease-free and overall survival of patients with DLBCL.
authors.affiliation: Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Emiko
authors.initials: E
authors.lastname: Sakane-Ishikawa
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Nakatsuka
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tomita
authors.forename: Shigeki
authors.initials: S
authors.lastname: Fujita
authors.forename: Itsuko
authors.initials: I
authors.lastname: Nakamichi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Takakuwa
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Shirou
authors.initials: S
authors.lastname: Fukuhara
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
authors.forename: Akihisa
authors.initials: A
authors.lastname: Kanamaru
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Soma
authors.forename: Machiko
authors.initials: M
authors.lastname: Tsukaguchi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Igarashi
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Kanakura
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Aozasa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050976:Basic-Leucine Zipper Transcription Factors / Q000235:genetics* / Q000378:metabolism*; D014408:Biomarkers, Tumor; D002277:Carcinoma / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000378:metabolism*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
chemical_list: C491123:BACH2 protein, human; D050976:Basic-Leucine Zipper Transcription Factors; D014408:Biomarkers, Tumor; D012333:RNA, Messenger